scispace - formally typeset
Open AccessJournal ArticleDOI

Development of an Intranasal Gel for the Delivery of a Broadly Acting Subunit Influenza Vaccine.

TLDR
Overall, this study indicates the utility of an intranasal gel for the delivery of COBRAs for the generation of serum and mucosal humoral responses.
Abstract
Influenza virus is a major cause of death on a global scale. Seasonal vaccines have been developed to combat influenza; however, they are not always highly effective. One strategy to develop a more broadly active influenza vaccine is the use of multiple rounds of layered consensus buildings to generate recombinant antigens, termed computationally optimized broadly reactive antigen (COBRA). Immunization with the COBRA hemagglutinin (HA) can elicit broad protection against multiple strains of a single influenza subtype (e.g., H1N1). We formulated a COBRA H1 HA with a stimulator of interferon genes agonist cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) into a nasal gel for vaccination against influenza. The gel formulation was designed to increase mucoadhesion and nasal retention of the antigen and adjuvant to promote a strong mucosal response. It consisted of a Schiff base-crosslinked hydrogel between branched polyethyleneimine and oxidized dextran. Following a prime-boost-boost schedule, an intranasal gel containing cGAMP and model antigen ovalbumin (OVA) led to the faster generation of serum IgG, IgG1, and IgG2c and significantly greater serum IgG1 levels on day 42 compared to soluble controls. Additionally, OVA-specific IgA was detected in nasal, vaginal, and fecal samples for all groups, except the vehicle control. When the COBRA HA was given intranasally in a prime-boost schedule, the mice receiving the gel containing the COBRA and cGAMP had significantly higher serum IgG and IgG2c at day 41 compared to all groups, and only this group had IgA levels above the background in vaginal, nasal, and fecal samples. Overall, this study indicates the utility of an intranasal gel for the delivery of COBRAs for the generation of serum and mucosal humoral responses.

read more

Citations
More filters
Journal ArticleDOI

Mucosal immune responses to infection and vaccination in the respiratory tract

TL;DR: Hewitt et al. as discussed by the authors reviewed the innate and adaptive immune responses in the lung and airways following infection and vaccination, with particular focus on influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Journal ArticleDOI

STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant.

TL;DR: In this article , the authors used an adjuvant comprised of a Stimulator of Interferon Genes (STING) agonist incorporated in a scalable microparticle platform to achieve durable protection against the influenza virus.
Journal ArticleDOI

Vinyl Sulfone-functionalized Acetalated Dextran Microparticles as a Subunit Broadly Acting Influenza Vaccine

TL;DR: In this article , the ACE-DEX microparticles (MPs) were used to conjugate COBRA to the surface and encapsulate the STING agonist cGAMP to form a broadly active influenza vaccine.
Journal ArticleDOI

cGAMP the travelling messenger

TL;DR: In this article , the authors describe the fast-paced discovery of the mechanisms by which 2'3'-cGAMP can be transported and highlight the diseases where they are important and detail how this change in perspective can be applied to vaccine design, cancer immunotherapies and treatment of cGAS-STING associated disease.
Journal ArticleDOI

Hydrogels for Mucosal Drug Delivery.

TL;DR: In this paper, the authors discuss hydrogels as an attractive means for local delivery of therapeutics to address a range of conditions affecting the eye, nose, oral cavity, gastrointestinal, urinary bladder, and vaginal tracts.
References
More filters
Journal ArticleDOI

Mucosal vaccines: the promise and the challenge

TL;DR: Current research is providing new insights into the function of mucosal tissues and the interplay of innate and adaptive immune responses that results in immune protection at mucosal surfaces that promise to accelerate the development and testing of new mucosal vaccines against many human diseases including HIV/AIDS.
Journal ArticleDOI

Mucoadhesive drug delivery systems.

TL;DR: This review article aims to provide an overview of the various aspects of mucoadhesion,Mucoadhesive materials, factors affecting muco adhesion, evaluating methods, and finally various mucoADhesive drug delivery systems (buccal, nasal, ocular, gastro, vaginal, and rectal).
Journal ArticleDOI

Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies

TL;DR: A systematic review and meta-analysis of Influenza vaccine effectiveness (VE) found vaccines provided substantial protection against H1N1pdm09, H1n1 (pre-2009), and type B, and reduced Protection against H3N2.
Journal ArticleDOI

Thermal mapping of the airways in humans

TL;DR: Data demonstrate that in the course of conditioning inspired air the intrathoracic and intrapulmonic airways undergo profound thermal changes that extend well into the periphery of the lung.
Related Papers (5)
Trending Questions (1)
Does the nasal influenza vaccine target the brai?

The provided paper does not mention anything about the nasal influenza vaccine targeting the brain.